Evidence map›Paper›PMID 33852858›Full record

ArticleCell reports2021

Cellular mRNA triggers structural transformation of Ebola virus matrix protein VP40 to its essential regulatory form.

Sara Landeras-Bueno, Hal Wasserman, Glenn Oliveira, Zachary L VanAernum, Florian Busch, Zhe Li Salie, Vicki H Wysocki, Kristian Andersen, Erica Ollmann Saphire

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.International journal of molecular sciences · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sara Landeras-BuenoLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Hal WassermanLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Glenn OliveiraDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Zachary L VanAernumDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA; Resource for Native Mass Spectrometry Guided Structural Biology, The Ohio State University, Columbus, OH 43210, USA.
Florian BuschDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA; Resource for Native Mass Spectrometry Guided Structural Biology, The Ohio State University, Columbus, OH 43210, USA.
Zhe Li SalieLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Vicki H WysockiDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA; Resource for Native Mass Spectrometry Guided Structural Biology, The Ohio State University, Columbus, OH 43210, USA.
Kristian AndersenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: andersen@scripps.edu.
Erica Ollmann SaphireLa Jolla Institute for Immunology, La Jolla, CA 92037, USA. Electronic address: erica@lji.org.
La Jolla Institute for Immunology · USThe Ohio State University · USScripps Research Institute · US

Funding

Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Waters Select Series Cyclic IMS for P41 Native MS Resource Application to Alzheimer's DiseaseP41GM128577 · NIGMS · OHIO STATE UNIVERSITY · PI SOMOGYI, ARPAD · 2018 to 2022
$7.6M
NIAID NIH HHS U19 AI135995NIGMS NIH HHS P41 GM103393NIGMS NIH HHS P41 GM128577
6 · The paper itself

Abstract

The Ebola virus matrix protein VP40 forms distinct structures linked to distinct functions in the virus life cycle. Dimeric VP40 is a structural protein associated with virus assembly, while octameric, ring-shaped VP40 is associated with transcriptional control. In this study, we show that suitable nucleic acid is sufficient to trigger a dynamic transformation of VP40 dimer into the octameric ring. Deep sequencing reveals a binding preference of the VP40 ring for the 3' untranslated region of cellular mRNA and a guanine- and adenine-rich binding motif. Complementary analyses of the nucleic-acid-induced VP40 ring by native mass spectrometry, electron microscopy, and X-ray crystal structures at 1.8 and 1.4 Å resolution reveal the stoichiometry of RNA binding, as well as an interface involving a key guanine nucleotide. The host factor-induced structural transformation of protein structure in response to specific RNA triggers in the Ebola virus life cycle presents unique opportunities for therapeutic inhibition.

Indexed as

3' Untranslated RegionsBinding SitesCrystallography, X-RayEbolavirusEscherichia coliGene ExpressionGuanineHEK293 CellsHigh-Throughput Nucleotide SequencingHost-Pathogen InteractionsHumansModels, MolecularNucleoproteinsNucleotide MotifsProtein BindingProtein Conformation, alpha-Helical3' Untranslated RegionsGuanineNucleoproteinsnucleoprotein VP40, Ebola virusRecombinant ProteinsViral Core Proteins3′ UTRcrystal structuredeep sequencingebolavirusEbola virusmatrix proteinmRNAnative mass spectrometrytransformer proteinVP40

Identifiers

PMID33852858
PMCPMC8568338
OpenAlexW3156401441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.